糖尿病肾病炎症生物标志物的研究进展

摘要
图/表
参考文献(38)
相关文章 (15)

全文: PDF (493 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要糖尿病肾病（DN）是由长期糖尿病（DM）所致的肾脏微血管病变，也是导致终末期肾脏病的主要原因。DN的发病机制涉及广泛，近年的研究表明炎症在其发病过程中起关键作用。在DM患者肾组织中发现细胞黏附分子、生长因子、趋化因子和促炎性细胞因子等表达增加，且与肾功能损伤密切相关。本文讨论了超敏C反应蛋白、中性粒细胞计数与淋巴细胞计数之比、正五聚蛋白3、肿瘤坏死因子-α及其受体、白细胞介素、Nod样受体蛋白3炎症小体、黏附分子、单核细胞趋化蛋白-1等8种与DN发病密切相关的炎症因子，旨在为监测DM患者肾功能变化及早期治疗提供新的思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	方雅萱钟柯倪清颖何振洋杨波

关键词 ：糖尿病肾病, 炎症因子, 生物标志物, 炎症反应, 微炎症

Abstract：Diabetic nephropathy (DN) is a renal microvascular disease caused by long-term diabetes mellitus (DM), which is also the main cause of end-stage kidney disease. The pathogenesis of DN involves a wide range. Recent studies have shown that inflammation plays a key role in the pathogenesis of DN. Increased expression of cell adhesion molecules, growth factors, chemokines, and pro-inflammatory cytokines is found in the renal tissues of DM patients, which is closely related to renal function injury. Eight inflammatory factors closely related to the pathogenesis of DN, including high sensitivity C-reactive protein, ratio of neutrophil count to lymphocyte count, pentraxin 3, tumor necrosis factor-α and its receptor, interleukins, Nod-like receptor protein 3 inflammasome, adhesion molecule and monocyte chemoattractant protein-1 are discussed in this paper, aiming to provide a new idea for monitoring the renal function changes and early treatment of DM patients.

Key words： Diabetic nephropathy Inflammatory factors Biomarkers Inflammatory Microinflammation

基金资助:国家自然科学基金资助项目（81774065）。

通讯作者: 杨波（1982.3-），男，博士，副主任医师；研究方向：中西医结合肾病临床与基础研究。

作者简介: 方雅萱（1996.9-），女，天津中医药大学第一附属医院2019级中医内科学专业在读硕士研究生；研究方向：中医内科学肾脏病。

引用本文:

方雅萱钟柯倪清颖何振洋杨波. 糖尿病肾病炎症生物标志物的研究进展[J]. 中国医药导报, 2021, 18(35): 38-41.
FANG Yaxuan ZHONG Ke NI Qingying HE Zhenyang YANG Bo. Research progress of inflammatory biomarkers of diabetic nephropathy#br#. 中国医药导报, 2021, 18(35): 38-41.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I35/38

[1] Cole JB，Florez JC. Genetics of diabetes mellitus and diabetes complications [J]. Nat Rev Nephrol，2020，16（7）：377-390.
[2] Luk AOY，Ke C，Lau ESH，et al. Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong：A retrospective cohort study [J]. PLoS Med，2020，17（2）：e1003052.
[3] Wang M，Gong WW，Pan J，et al. Incidence and Time Trends of Type 2 Diabetes Mellitus among Adults in Zhejiang Province，China，2007-2017 [J]. J Diabetes Res，2020， 2020：2597953.
[4] Lytvyn Y，Bjornstad P，van Raalte DH，et al. The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications [J]. Endocr Rev，2020，41（2）：202-231.
[5] Matoba K，Takeda Y，Nagai Y，et al. Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease [J]. Int J Mol Sci，2019，20（14）：3393.
[6] Tang SCW，Yiu WH. Innate immunity in diabetic kidney disease [J]. Nat Rev Nephrol，2020，16（4）：206-222.
[7] Sinha SK，Nicholas SB，Sung JH，et al. hs-CRP Is Associated With Incident Diabetic Nephropathy：Findings From the Jackson Heart Study [J]. Diabetes Care，2019，42（11）：2083-2089.
[8] Liu F，Chen HY，Huang XR，et al. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes [J]. Diabetologia，2011，54（10）：2713-2723.
[9] Chung FM，Tsai JC，Chang DM，et al. Peripheral total and differential leukocyte count in diabetic nephropathy： the relationship of plasma leptin to leukocytosis [J]. Diabetes Care，2005，28（7）：1710-1717.
[10] Azab B，Daoud J，Naeem FB，et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients （3-year follow-up study）[J]. Ren Fail，2012，34（5）：571-576.
[11] Zhang J，Zhang R，Wang Y，et al. Effects of neutrophil-lymphocyte ratio on renal function and histologic lesions in patients with diabetic nephropathy [J]. Nephrology（Carlton），2019，24（11）：1115-1121.
[12] Rathore M，Girard C，Ohanna M，et al. Cancer cell-derived long pentraxin 3 （PTX3） promotes melanoma migration through a toll-like receptor 4 （TLR4）/NF-κB signaling pathway [J]. Oncogene，2019，38（30）：5873-5889.
[13] Uzun S，Ozari M，Gursu M，et al. Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3 [J]. Ren Fail，2016，38（8）：1193-1198.
[14] Suliman ME，Yilmaz MI，Carrero JJ，et al. Novel links between the long pentraxin 3，endothelial dysfunction，and albuminuria in early and advanced chronic kidney disease [J]. Clin J Am Soc Nephrol，2008，3（4）：976-985.
[15] Fathy SA，Mohamed MR，Ali MAM，et al. Influence of IL-6，IL-10，IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients [J]. Biomarkers，2019，24（1）：43-55.
[16] Kalantarinia K，Awad AS，Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats [J]. Kidney Int，2003，64（4）：1208-1213.
[17] Cao L，Boston A，Jegede O，et al. Inflammation and Kidney Injury in Diabetic African American Men [J]. J Diabetes Res，2019，2019：5359635.
[18] Niewczas MA，Gohda T，Skupien J，et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes [J]. J Am Soc Nephrol，2012，23（3）：507-15.
[19] Ridker PM. Targeting Interleukin-1 and Interleukin-6： The Time Has Come to Aggressively Address Residual Inflammatory Risk [J]. J Am Coll Cardiol，2020，76（15）：1774-1776.
[20] Murakami M，Kamimura D，Hirano T. Pleiotropy and Specificity：Insights from the Interleukin 6 Family of Cytokines [J]. Immunity，2019，50（4）：812-831.
[21] Kang S，Tanaka T，Narazaki M，et al. Targeting Interleukin-6 Signaling in Clinic [J]. Immunity，2019，50（4）：1007-1023.
[22] Choi YH，Lim EJ，Kim SW，et al. IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells [J]. J Immunother Cancer，2019，7（1）：211.
[23] Lei Y，Devarapu SK，Motrapu M，et al. Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes [J]. Front Immunol，2019，10：1223.
[24] Sangoi MB，Carvalho JAM，Guarda NS，et al. Association between Urinary Levels of Interleukin-6，Interleukin-10 and Tumor Necrosis Factor-Alpha with Glomerular and Tubular Damage Indicators in Patients with Type 2 Diabetes [J]. Clin Lab，2019，65（11）.
[25] Yaribeygi H，Atkin SL，Sahebkar A. Interleukin-18 and diabetic nephropathy：A review [J]. J Cell Physiol，2019， 234（5）：5674-5682.
[26] Chi K，Geng X，Liu C，et al. Research Progress on the Role of Inflammasomes in Kidney Disease [J]. Mediators Inflamm，2020，2020：8032797.
[27] Fu Y，Wu N，Zhao D. Function of NLRP3 in the Pathogenesis and Development of Diabetic Nephropathy [J]. Med Sci Monit，2017，23：3878-3884.
[28] El-Horany HE，Abd-Ellatif RN，Watany M，et al. NLRP3 expression and urinary HSP72 in relation to biomarkers of inflammation and oxidative stress in diabetic nephropathy patients [J]. IUBMB Life，2017，69（8）：623-630.
[29] Wu M，Han W，Song S，et al. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice [J]. Mol Cell Endocrinol，2018，478：115-125.
[30] Garrido W，Jara C，Torres A，et al. Blockade of the Adenosine A3 Receptor Attenuates Caspase 1 Activation in Renal Tubule Epithelial Cells and Decreases Interleukins IL-1β and IL-18 in Diabetic Rats [J]. Int J Mol Sci，2019，20（18）：4531.
[31] Bui TM，Wiesolek HL，Sumagin R. ICAM-1： A master regulator of cellular responses in inflammation，injury resolution，and tumorigenesis [J]. J Leukoc Biol，2020， 108（3）：787-799.
[32] Karimi Z，Kahe F，Jamil A，et al. Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria [J]. Diabetes Metab Syndr，2018，12（3）：365-368.
[33] Astrup AS，Tarnow L，Pietraszek L，et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years：association with mortality and decline of glomerular filtration rate [J]. Diabetes Care，2008，31（6）：1170-1176.
[34] Al-Rubeaan K，Nawaz SS，Youssef AM，et al. IL-18，VCAM-1 and P-selectin as early biomarkers in normoalbuminuric Type 2 diabetes patients [J]. Biomark Med，2019，13（6）：467-478.
[35] Siddiqui K，Joy SS，Al-Rubeaan K. Association of urinary monocyte chemoattractant protein-1 （MCP-1） and kidney injury molecule-1（KIM-1）with risk factors of diabetic kidney disease in type 2 diabetes patients [J]. Int Urol Nephrol，2019，51（8）：1379-1386.
[36] Fufaa GD，Weil EJ，Nelson RG，et al. CKD Biomarkers Consortium and the RASS Investigators. Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus [J]. Nephrol Dial Transplant，2015，30（4）：599-606.
[37] Comai G，Malvi D，Angeletti A，et al. Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis [J]. Am J Nephrol，2019，50（1）：29-36.
[38] Sousa GR，Pober D，Galderisi A，et al. Glycemic Control，Cardiac Autoimmunity，and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus [J]. Circulation，2019，139（6）：730-743.